Gilenya not effective for slowing disease progression in primary progressive MS
February 5, 2016Following our earlier report in 2014 of disappointing preliminary results from a phase III clinical trial of Gilenya (fingolimod) in people with primary progressive MS (PPMS), the full results of this trial have recently been published in prestigious medical journal The Lancet. To read more, click on the link below:
Gilenya not effective for slowing disease progression in primary progressive MS
Article courtesy of MS Research Australia www.msra.org.au